Despite recent advances in the management of colorectal cancer, metastatic disease
remains challenging, and patients are rarely cured. However, a better understanding of the …

There is a clear and unmet clinical need for biomarkers to predict responsiveness to
chemotherapy for cancer. We developed an in vitro test based on patient-derived tumor …

Background This systematic review and meta-analysis aims to evaluate the additive effect of
bevacizumab when combined with first-line chemotherapy in metastatic colorectal cancer …

Background Treating colorectal cancer (CRC) continues to be a clinical challenge. Studies
have shown that epithelial-mesenchymal transition (EMT) is a critical step in tumor …

The proportion of patients with metastatic colorectal cancer (mCRC) receiving second or
further lines of treatment has not been widely studied. To shed light on this issue, we …

Background There are few clinical challenges associated with the treatment of colorectal
cancer (CRC). Studies have shown that TGF-β plays a crucial role in CRC. Importantly …

Colorectal cancer (CRC) is a common clinical cancer that remains incurable in most cases.
miRNAs are reported to play a part in the development of various tumors. In the present …

Anti-EGFR mAb (cetuximab or panitumumab) and anti-VEGF mAb (bevacizumab) are the
two main targeted agents available for RAS wild-type (WT) metastatic colorectal cancer …

Poor survival among colorectal cancer (CRC) patients has been widely associated with
clinico-epidemiological features and treatment regimen. In Jiangsu (China), however, it is …

Introduction Survival in metastatic colorectal cancer is worse than expected in the United
Kingdom. Real-world data are needed to better understand UK-specific treatment practices …